SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
PENINSULA, NCT06318286: Study of Pembrolizumab Plus Chemotherapy With Lenvatinib for Malignant Pleural Mesothelioma |
|
|
| Not yet recruiting | 2 | 25 | Japan | Lenvatinib, E7080, Pemetrexed, Cisplatin/Carboplatin, Pembrolizumab, MK-3475 | Hyogo Medical University, Merck Sharp & Dohme LLC | Malignant Pleural Mesothelioma | 04/26 | 10/26 | | |
